Description
DKK1 Antibody | 30-346 | Gentaur UK, US & Europe Distribution
Host: Rabbit
Reactivity: Human, Rat, Dog
Homology: N/A
Immunogen: Antibody produced in rabbits immunized with a synthetic peptide corresponding a region of human DKK1.
Research Area: Cancer, Signal Transduction, Growth Factors
Tested Application: E, WB
Application: DKK1 antibody can be used for detection of DKK1 by ELISA at 1:312500. DKK1 antibody can be used for detection of DKK1 by western blot at 2.5 μg/mL, and HRP conjugated secondary antibody should be diluted 1:50, 000 - 100, 000.
Specificiy: N/A
Positive Control 1: Cat. No. 1211 - HepG2 Cell Lysate
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: 26 kDa
Validation: N/A
Isoform: N/A
Purification: Antibody is purified by protein A chromatography method.
Clonality: Polyclonal
Clone: N/A
Isotype: N/A
Conjugate: Unconjugated
Physical State: Liquid
Buffer: Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
Concentration: batch dependent
Storage Condition: For short periods of storage (days) store at 4˚C. For longer periods of storage, store DKK1 antibody at -20˚C. As with any antibody avoid repeat freeze-thaw cycles.
Alternate Name: DKK1, DKK-1, SK
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: DKK1 is a protein that is a member of the dickkopf family. It is a secreted protein with two cysteine rich regions and is involved in embryonic development through its inhibition of the WNT signaling pathway. Elevated levels of DKK1 in bone marrow plasma and peripheral blood is associated with the presence of osteolytic bone lesions in patients with multiple myeloma.This gene encodes a protein that is a member of the dickkopf family. It is a secreted protein with two cysteine rich regions and is involved in embryonic development through its inhibition of the WNT signaling pathway. Elevated levels of DKK1 in bone marrow plasma and peripheral blood is associated with the presence of osteolytic bone lesions in patients with multiple myeloma.